STOCKS TELEGRAPH

Author: ST Staff

  • Why is Greenwich LifeSciences, Inc. (GLSI) stock popping high in Pre-Market trading?

    Why is Greenwich LifeSciences, Inc. (GLSI) stock popping high in Pre-Market trading?

    Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, today reported the Robust Immune Response Phase IIb Data after which the GLSI stock price surged by 26.73% to reach $64.00 a share as of this writing. Today’s news of Greenwich has made the momentum for GLSI stock which was down at the previous trading session and closed with a 1.52% drop. Let’s try to figure out more about GLSI stock.

    What’s happening?

    Greenwich LifeSciences is mainly focused on the development of GP2 which is the immunotherapy to treat or prevent breast cancer in patients having a history of surgery. GLSI announced the Phase IIb clinical trial Data following the 5 years at the 2021 AACR Annual Meetingwhich supports the previously reported outcome of 0% Metastatic Breast Cancer Recurrences. The AACR published the final 5-year immune response data today and graphical posters of immune response data will be published on Saturday, April 10, 2021.

    The GP2 manufacturing is expected to complete in the period between the second and third quarter of 2021 and the presentation of the updated design of the Phase III clinical trial will be in the period between the third and fourth quarter of 2021.

    A deep look at Greenwich:

    Research shows that one out of eight women develops breast cancer, and one out of 833 men develops breast cancer in the United States and Greenwich LifeSciences is acting as the leader in the battle against breast cancer. Before December 2020, GLSI stock share price was not higher than $6 despite so much effort by the management, but the month of December did wonders for the GLSI stock as its per-share price skyrocketed to $70 as of December 10, 2020, and then the GLSI lowered back to $36 at the end of 2020.

    Conclusion:

    GLSI stock price is rising in the pre-market today in response to the reporting of data for robust immune response. GLSI stock has developed significantly for the last few months due to its continuous efforts against breast cancer. In a nutshell GLSI stock can be a good bet in the long run.

  • Brickell Biotech, Inc. (BBI) stock falls in Pre-Market: Why is it so?

    Brickell Biotech, Inc. (BBI) stock falls in Pre-Market: Why is it so?

    Brickell Biotech, Inc. (BBI) announced its fourth-quarter and full-year financial results of 2020 after which the BBI stock happened to be red, and its price saw a downtrend of 2.75% in today’s pre-market to drop at $1.06 a share at the time of this writing. BBI was gaining in the previous trading session and closed with a 0.93% gain. Let’s discuss the earnings report in detail.

    Fourth Quarter Results:

    • BBI stock recorded revenue of $27 thousand in the fourth quarter of 2020 which is significantly less than the $0.7 million in the same quarter of the prior year. The reduction in the revenue was mainly due to the winding down of the safety study of sofpironium bromide gel as well as various clinical activities in the first quarter of 2020.
    • Reduction of clinical activities resulted in less research and development costs of $4.6 million in the fourth quarter of 2020 as compared to $6.6 million in the same tenure of the previous year.
    • General and administrative expenses were reduced to $2.9 million of BBI stock as compared to$4.9 million in the same period of the previous year. This reduction is due to the reduction in cost related to the merger with Vical Incorporated, reduced impairment expenses, and other reduced miscellaneous expenses.

    Full Year Financial Results:

    • BBI stock generated $1.8 million revenue in 2020, a huge decrease as compared to the $7.9 million revenue of 2020. This decrease owes to the reduced clinical activities in 2020.
    • Research and development expenses reduced to $11.2 million in 2020 as compared to $20.2 million in 2019.
    • General and administrative expenses of BBI stock reduced to $11.6 million in 2020 while these were $12.2 in the prior-year period.
    • As of December 31, 2020, BBI recorded a net loss of $20.9 million as compared to a net loss of $23.9 million as of December 31, 2019.
    • BBI stock had cash and cash equivalents and market securities of $30.1 million at the end of 2020 while these were $11.7 million at the end of 2019.

    Recent Developments of BBI stock:

    Brickell Biotech completed an equity financing in 2020 that resulted in $13.7 million net proceeds.Moreover, Brickell Biotech initiated the enrollment of U.S. Phase 3 Cardigan I and Cardigan II studies related to sofpironium bromide gel and exceeded 50% enrollment in the former. Launching of ECCLOCK in Japan, publishing of phase 3 study results by Kaken, and completion of  Phase 1/2 study of investigational COVID-19 vaccine candidate and initiation of Phase 2/3 study in Japan are some other major business developments of BBI stock.

    Conclusion:

    Investors are responding to the earnings report released by BBI stock today. Results are not much satisfactory by BBI stock in 2020 as compared to 2019 as revenue as well as operating expenses decreased significantly which points to the decline in growth over the year.

  • Sogou Inc. (SOGO) stock soared in the pre-market trading session: here’s why

    SogouInc, (SOGO) stock rose to $8.70 in the premarket trading session at the time of writing. This is a 5.84% rise. In the previous trading session, SOGO stock closed $8.22 which is a 3.40% gain. The number of shares that exchanged hands are 1.02 million which is higher than the average daily volume (within the past 50 days) of 0.73 million shares. In the last 12 months, SOGO stock has soared by 141.06% and in the past six months it shed -7.33%. Following that, the past three months the stock had lost -0.12%. In the past week the SOGO stock moved up by 8.87%. Right now, Sogou has a current market of $3.13 billion and the outstanding shares stood at 392.21 million.

    The positive movement in the SOGO stock recent pre-market trading session is due to the announcement on 30th March, by the company for being given the title Winner of 2021 Artificial Intelligence Excellence award.

    Sogou Inc. is a leading internet and AI company in China

    Sogou Inc. (SOGO) is a Chinese Internet Company which is an innovator of search and search-related services in People’s Republic of China. It is also a leader in China’s internet industry. In China, SOGO has become the world’s second-largest search engine on mobile platforms and has 4th largest Monthly Active Users in the country.

    Sogou’s product offerings and services includes Sogou Input Method which is a language input software for PC and mobile users. It also provides web games and mobile games related internet based operation services.

    Sogou Inc. is the winner of Artificial Intelligence Excellence award

    Sogou Inc. announced that it has been awarded Business Intelligence Group’s winner of the Artificial Intelligence Excellence.  The Business Intelligence Group analyzes this award based on the company’s artificial intelligence design and innovation. The judging panel consists of highly experienced business executives which shows that this competition is This award also examines the most significant and practical impacts it has or will have on challenges and problems people face. Business Intelligence Group (BIG) has had IBM and Johnson Controls like tech giants in the past who have been the winner of this award.

    Giving free of charge annual hardcopy to shareholders

    Previously on 18th March, Sogou stock had announced that it had filed a 20-F file with the Security and Exchange Commission which shows its annual report for the year ended 31st December 2020. The company has stated that the hard copy of the annual report will be given to any shareholder or holder of Company’s American Depositary Shares upon request and free of charge.

    SOGO stock excels in the AI-tech as well

    There is no doubt that China is leading the AI-tech race with its state-of-the-art technologies and innovations; Sogou Inc. is also actively participating in this race. Sogou Inc. has made a riveting breakthrough by creating the world’s first AI News Anchor which can be rendered to any scenarios and has life-like features. During COVID-19 pandemic the SOGO stock launched smart applications for the general public to gain authentic and authoritative news updates and public facilitating knowledge.

  • TherapeuticsMD Inc. (TXMD) stock soared in the pre-market trading session: here’s why

    TherapeuticsMD Inc. (TXMD) stock recently traded in the premarket at $1.57 which is an 18.94% rise. TXMD’s stock closed at $1.32 which is the same price to its prior session close thus a 0.00% change. The number of shares that exchanged hands in the day was 6.57 million. However, this was lower than the average daily volume of 17.1 million shares within the past 50 days. The volume in the past week was down by -1.49%. TXMD stock has risen by 47.67% in the last 12 months but shed -17.50%. In the last 3 months, it then gained 2.33%. Furthermore, the company’s current market share values at $493.52 million and its outstanding shares stood at 286.69 million.

    The recent positive movement of TXMD stock in the recent pre-market trading session has come adjacent to the press release by the Company announcing approval of its Hormone Replacement Therapy (HRT)

    TherapeuticsMD healthcare provides special care for women

    TherapeuticsMD, Inc. is a healthcare company which is focused towards the production of novel and unique products. These healthcare products are made specifically for women and innovation comes through the design and accordance with the unmet needs/challenges of women. The company looks at various experiences and stages of a woman’s life to keep in mind while designing these products especially for menopause, family planning and reproductive health.

    Approval of HRT capsule, BIJUVA® in UK and BIJUVE®in Belgium.

    TherapeuticsMDInc (TXMD) along with its collaborating partner Theramex announced the approval of BIJUVE® Capsules in the United Kingdom and under the trade name BIJUVA® in Belgium. Theramex is a global specialty pharmaceutical company and like TXMD stock it is dedicated to women’s health. Its vision is to be a lifetime partner for women and has a portfolio of contraceptive, fertility, menopause, and osteoporosis related products covered under established brand names.

    United Kingdom and Belgium are not the first countries where the Hormone Replacement Therapy has been released; USA had BIJUVA made commercially available in April 2019, while Canada and Israel have these commercially available as well. However BIJUVA is Europe’s first and only oral HRT with bio-identical hormones; specifically Estradiol and micronized Progesterone made available.

    Theramex signed an exclusive licensing and supply agreement with TherapeuticsMD Inc. in June 2019, to make BIJUVA available outside of these countries, especially in the European market. This agreement states Theramex paying TherapeuticsMD, certain royalties and milestone fees based upon aggregate net sales.

    The approval in European countries is a major positive move for TXMD stock

    The process of regulatory approval was a decentralized procedure that took place in February and afterwards each country has its own terms and conditions for medical approval. The approval for other significant EU countries will take place shorty, as expected by Theramex. It is possible to see a positive trend of TXMD stock maintain for longer period if commercial availability and approvals come further down the year.

  • Provention Bio Inc. (PRVB) stock plunged in the after-hours trading session: here’s why

    Provention Bio Inc. (PRVB) stock had recently traded at $6.03 at the time of writing which is a -38.06% downward movement in the after-market trading session. PRVB stock dropped -2.36% which closed Thursday’s session at $9.73. The stock volume was 1.56 million shares which was higher than the average daily volume of 0.93 million shares within the past 50 days. In the past 12 months, the PRVB shares have moved up by 16.03%, however, in the past six months and past 3 months, it lost -31.97% and -44.02%. In the past week, the shares went down by -7.24%. Furthermore, PRVB has a current market of $568.73 million and its outstanding shares total 56.63 million.

    The recent pattern of downward movement in after-hours trading has come adjacent with the announcement made by PRVB stock stating the FDA has found deficiencies for Teplizumab’s application approval.

    Insight on Provention Bio’s background

    Provention Bio Inc. (PRVB) is a biopharmaceutical company that specifically focuses on the development of investigational therapies. The focus on investigative therapies is to tackle in an innovative and effective way to treat the diseases which can be debilitating and can also cause life-threatening immune-mediated diseases.

    PRVB stock’s Pipeline Projects

    Provention Bio Inc (PRVB) has many projects in its pipeline which include additional clinical-stage product candidates specifically for celiac and lupus treatment as well as other autoimmune diseases. These are candidates that have shown the proof of concept and proof of mechanism for the pre-clinical or clinical studies.

    Announcement of FDA’s update on Biologic License Application of Teplizumab

    Provention Bio Inc (PRVB) announced on 8th April 2021 that it received a notification from the Food and Drug Administration that mentioned finding deficiencies on the subject of post-marketing requirements for the review of the ongoing Biologic License Application process of teplizumab.

    Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb). It is used to delay or prevent the onset of type 1 diabetes (T1D) in at-risk individuals. Multiple clinical studies with up to 1000 subjects have proven the efficacy of the drug for T1D by preserving beta-cell function – which is responsible for the body’s insulin production. Subsequently, the clinical trials also showed teplizumab to make the patients less reliant on external insulin. The FDA had accorded teplizumab with Breakthrough Therapy Designation to expedite the review of the drug.

    Outlook of PRVB stock

    However, despite the downturn of the stock, market sentiment may change drastically given Provention Bio Inc.’s optimism regarding the application of teplizumab. The CEO Ashleigh Palmer remained headstrong and confident about the review and is adamant on fulfilling the further data requirements of FDA. A conference call has been scheduled by the firm to discuss the recent developments and an audio webcast will also be available on the Company’s website afterwards. Moreover, the FDA has also stated that notification does not communicate the final decision – indicating towards a possible positive outcome. The Food and Drug Administration authority has also shown willingness to discuss the additional data requirements along with the ongoing review. The fulfilment of the additional requirements will be the deciding factor in FDA’s final decision regarding teplizumab’s BLA.

  • Will United States Antimony (UAMY) stock Continue to Fall?

    China is the biggest competitor of US based mining companies, producing up to 90% of the world’s antimony. Because of this increasingly stiff competition and low prices of metals, US miners have struggled for the last 10 years. United States Antimony (UAMY) is one of the companies that has benefitted from the pandemic. Since production in China has suffered while global demand has gone up, UAMY stocks have seen a substantial (albeit not consistent) increase in price. Sitting at USD$0.50 around the end of 2019, it saw its highest ever prices in February of 2021, surpassing the USD$2.00 mark. Currently, it sits at USD$1.23

    Why is the Government Helping UAMY?

    Given that there is a risk of China restricting exports of strategic and precious metal to the US, UAMY was given a USD$510,528.00 grant by the government to stockpile antimony, which is used as a main component of ammunition as well as in fire-resistant materials. While not a monumental grant, it likely instilled confidence in investors that one of the few domestic producers of antimony would be scaffolded by the government because of how crucial the supply of antimony is.

    Where does UAMY Stand at the Moment?

    Having raised USD$14.3 million through direct offerings of its common stock (which is close to 10 times the amount of money UAMY had available to invest at the end of their last quarter), UAMY is primed to invest that capital and usher in further growth. It plans to put that money towards improving infrastructures at their antimony set up in Mexico and Montana, as well as of their zeolite project in Idaho. This capital will also be used to fund their drill program in Los Juarez, as well as cover general corporate expenses and reduce debt.

    What Explains UAMY’s Current Position?

    Despite these developments, UAMYs recent track record is quite confounding. While revenue has been consistently declining at a rate of nearly 13% per annum, the share price has been rising by a compounded 23% every year. This could potentially be attributed to the rise of newer retail traders and investors who are less risk-averse than experienced traders who have experienced significant long-term corrections and crashes. To illustrate, Google shows a sharp increase in the search for the UAMY ticker over the past few months, but not the company itself.

  • What has Electro-Sensors (ELSE) recently been up to?

    What has Electro-Sensors (ELSE) recently been up to?

    Electro-Sensors Inc. (ELSE) shares dropped by -3.58% to trade at $5.11 in the current market, at the time of writing. ELSE stock previously closed at $5.30. The stock volume was 1.35 million shares, which is higher compared to the past 50 days’ volume of 0.23 million shares. In the past 12 months, ELSE shares had risen by 44.02% and had moved 15.22% in the past week. Furthermore, the ELSE stock had gained 23.54% over the past three months and 53.62% over the past six months. The current market for ELSE stock stands at $18.02 million with 3.4 million shares outstanding.

    The drop in the recent trading session does not correlate to any current news because Electro-Sensorshave kept a very low profile when it comes to recent news and developments.

    What industries and clients does Electro-Sensors serve?

    Electro-Sensors belongs to the technology sector. It is founded in 1968 and located in Minnesota. Electro is the leader of manufacturing and designing one of the most robust and dependable monitoring sensors and monitoring systems for hazardous situations. These products are demanded across multiple industries and applications. ELSE stock has served the industry of Grain, Feed & Milling, Bulk Materials Handling, General Manufacturing, Fuels Processing, Sugar Processing, Packing, Food Processing, Textile, Mining, Power Generation Plants, Water Utilities and Wastewater.

    Electro-Sensors product offerings

    The Scientific and Technical Instruments industry based company has served its customers and clients with a wide array of products which include bearing sensors, temperature sensors, vibration sensors, sensor targets, speed sensors, belt alignment sensors, motor drive control, wired hazard monitors, tachometers & counters, SG1000 position monitors and wireless hazard system.

    The most standard of these products are shipped within one to two days and they contain a warranty of 5 years. Electro-Sensors have certified itself to be an ISO9001-2015 quality certified company. Its recent most hyped product includes the HazardPROTM Wireless Hazard Monitoring System, which features an all-in-one monitoring protection for people, assets, products, and facilities. It provides and displays information in an intuitive format which is precise yet simple for users to read. For more details, visit the company’s website.

    Why Electro-Sensors has not been covered by media lately

    Part of the reason why Electro does not have any press-release or news on the mainstream media is because it has not made any major news or participation in main events. Also, many of the Expos, Conferences and Exchanges it had planned for 2020 had been postponed or cancelled. This was due to incidences related to the pandemic and lockdowns in 2020.

    On its website, it has announced that the International Association of Operative Miller (IAOM) canceled its 2020 conference but it will be there for the 2021 IAOM Conference & Expo that will take place on April 13-16 2021. Similarly, the 2021 GEAPS Exchange will take place in Columbus, Ohio on 6-9 August, which had also been canceled in 2020. In April, the ELSE stock will be exhibiting at the International Power & Bulks Solid Conference & Expo, happening from 27th to 29th.

  • Tesla (TSLA) Stock Continues To Soar After A Phenomenal Quarter

    Tesla (TSLA) Stock Continues To Soar After A Phenomenal Quarter

    Following the surge in value after Jan 2020 and the sequential correction, many doubted the integrity of TSLA’s second steep climb around the end of March in 2020. Fast Forward to 25th January 2021 and TSLA stock was priced at USD 900.40 for its highest value to date. Currently valued at just under USD 700 (a meteoric 700% increase from the start of 2020), TSLA saw a 2.36% jump at the last check on Thursday, April 8th, 2021.

    What happened?
    This jump coincided with the first quarterly delivery report for the year of 2021. Despite the automotive industry suffering across the board on account of a shortage of semiconductors, Tesla managed to have a record-breaking Q1 that shattered the expectations of analysts. With deliveries expected to be around 170,000, Q1 saw a whopping 184,800 deliveries that sets Tesla on the track to hit 750,000 deliveries for the year. This would be a 50% increase from the 500,000 deliveries fulfilled in 2020.

    How did it happen?
    There was a drop in deliveries of Model S and Model X vehicles from 12,200 deliveries in Q1 of 2020 to 2,020 deliveries in Q1 of 2021. However, the cessation of production and reduced deliveries of their pricier models can largely be attributed to the rolling out of newer versions of these models. This is sharply contrasted with Model 3 and Model Y vehicles reporting 76,200 combined deliveries in Q1 of 2020, with cumulative deliveries seeing a 140% increase to 182,780 deliveries in Q1 of 2021. Production of their Model Y started in Q4 of 2020 in China and plays a significant part in Tesla’s performance in 2021 so far, having been generally very well received.[4]

    What happens next?
    With such strong numbers and promising growth, investors have had their confidence in the company assured. This news in tandem with President Biden’s focus on the EV sector in the recently unveiled infrastructure budget plan has consolidated investor presence in the EV sector. Not just for Tesla, shares across the EV sector have seen a positive shift, now poised on the verge of further growth.

  • Bonso Electronics International Inc. (BNSO) Stock Rises 44%, What Are They Doing Right?

    April 7th, 2021 saw a meteoric 44% rise in the price of shares of Bonso Electronics International Inc. (BNSO) stock overnight. The jump from USD$6.86 to USD$9.89 came a week after BNSO stock released its financial results for the 6-month period ending 30th September 2020. These reports were promising, indicating a net income of USD$0.20 million and net revenue of USD$8.1 million. The net income for the same 6-month period in 2019 reported a USD$0.59 million net loss and net revenue of USD$4.4 million. The less than stellar numbers from 2019 are reflective of the struggling market succumbing to the chokehold of the pandemic, compounded with the termination of their leasing contract with a third party for their Shenzhen factory.

    How Did BNSO Thrive in a Struggling Economy?

    The CEO, Mr. Andrew So, attributed much of the success of the latest reported numbers to the growth in online sales, primarily of electronic pet products and weighing devices. With so many people being home-bound because of the pandemic, online sales in general increased (tempered by the reduced spending power in the midst of a struggling global economy). However, as contactless became the norm and buyers moved their purchasing online, so too did businesses with their selling. With increasing competition in the market space and reduced spending power of consumers, Mr. So warned against being complacent with the growth they had experienced, even suggesting it may not be sustainable.

    What Does the Future of BNSO Look Like?

    With this in mind, BNSO stock has both expanded and improved their product line with the release of electronic bathroom scales, as well as improvements to their existing products.[5] Following the cessation of their rental income from the leasing out of their Shenzhen factory, BNSO had anticipated acquiring the necessary government approvals to redevelop by September of 2020. At this time, however, they still predict another 12-months before the redevelopment of their Shenzhen factory will start. It is expected to take 3-4 years to complete, but they are hopeful it will prove to be financially lucrative in the longer run from the rental revenue generated. Until that time, BNSO stock has signed a short-term leasing contract to bridge that gap and capitalize on the rental income.

  • ORBCOMM Inc. (ORBC) stock is popping high today: What Going on?

    ORBCOMM Inc. (ORBC) stock is popping high today: What Going on?

    ORBCOMM Inc. (ORBC) has signed the definitive agreement to be acquired by the GI partner today after which the ORBC stock price surged by 52.18% to reach $11.52 a share as of this writing. ORBC stock was gloomy at the previous trading session and closed with a 3.07% drop. Let’s understand more about it.

    What’s happening?

    ORBCOMM Inc. (ORBC) is the solution provider of the Internet of Things in the United States and the globe. In connection with the recently announced agreement, ORBC stock will be acquired by the GI partner in an all-cash transaction that would value ORBCOMM at approximately $1.1 billion. The stockholders of ORBC stock would get $11.50 in cash per outstanding share of ORBC’s common stock upon the closing of the transaction which represent the nearly 52% premium to ORBC’s closing share price observed on April 7, 2021, and a 50% premium of 90 days volume-weighted average share price till April 7, 2021.

    ORBCOMM is focused on global expansion as well as development in its various areas for long-term growth. The investment by GI partner in connection with the above-mentioned agreement would help the ORBC stock in the increasing investment in its sales, marketing, and technology advancement and provide more flexibility to ORBCOMM as a privately held company.

    Recent Development:

    On April 6, 2021, ORBCOMM was selected by IWX Motor Freight in order to provide a solution related to cold chain telematics with the purpose of tracking, controlling, and monitoring the IWX refrigerated trailers. ORBC solution of cold chain monitors two-way temperature control as well as the location of the refrigerated shipments by ensuring the integrity and security of IWX freight in the whole shipment process.

    Conclusion:

    ORBC stock news about the definitive agreement with GI partner has captivated the attention of the investors as far as market sentiment is concerned. This new agreement will help ORBC stock in the overall growth in the long term. No doubt that technology is advancing day by day and this advancement would do wonders in the future. Hence tech companies must bring continuous innovation in their operations in order to survive in the future. That’s why companies like ORBCOMM are greatly focused on technology innovation. Hence it is better for investors having long-term prospects to do both technical and fundamental analysis of ORBC stock.